About the Company
innovative med concepts is an international trade and development company located in 1837 commons north drive, tuscaloosa, al, united states.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VIRI News
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –- Active Long-COVID characterized by immune ...
Virios Therapeutics, Inc.
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The firm engages in the development and commercialization of antiviral therapies to ...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to ...
Virios Therapeutics Inc Ordinary Shares VIRI
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Virios Therapeutics seeks global patent for antiviral combo
ATLANTA - Virios Therapeutics, Inc. (NASDAQ:VIRI), a biotechnology company specializing in antiviral therapies, announced a significant step in its intellectual property strategy. The World ...
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral ...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Chairman and CEO of Virios Therapeutics, Inc. “This is particularly encouraging given that our unique combination antiviral agents have demonstrated clinically and statistically significant ...
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms – ATLANTA, March 26, ...
Virios Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Virios Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Forward looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.
Loading the latest forecasts...